virus infects patients with chronic viral hepatitis, intraveThe aim of this work was to study the presence of the nous drug abusers, and organ or blood recipients. 2,4,5 To our hepatitis GB virus type C (HGBV-C) in liver and serum knowledge, the presence of HGBV-C RNA in children with samples of children with chronic viral hepatitis, the time chronic viral hepatitis has not yet been reported. course of changes in viral RNA, and the possible acquisi-We have retrospectively analyzed the presence of HGBVtion routes of infection. Frozen serum and liver samples C RNA in paired serum and liver samples from 58 children from 58 children with chronic hepatitis B (n Å 33) or C with chronic hepatitis B or C. We have also studied the time (n Å 25) were analyzed using polymerase chain reaction.course of changes in serum HGBV-C RNA in both treated Twenty-seven children had been included in different and untreated children with chronic viral hepatitis as well interferon trials. Two additional serum samples from the as the possible routes of HGBV-C transmission in infected HGBV-C-positive children as well as serum samples from children. properly stored at 020ЊC (serum samples) or in liquid nitrogen (liver mother. In the 3 children receiving alpha-interferon, samples). The mean age of the children was 12.1 { 3.9 years (range: HGBV-C RNA became undetectable during treatment al-2-16 years). Forty-six of 58 children had had abnormal alanine amithough it reappeared in 2 of them after therapy. In con-notransferase (ALT) levels for at least 1 year before the study start clusion, we found that 15% of children with chronic viral ( 21. Twenty-seven children had been included in different interferon Studies of HGBV-C RNA prevalence have shown that this (IFN) trials; in these cases, the first sample analyzed corresponded to the baseline sample of the trial.In the HGBV-C RNA-positive children two additional serum samples, apart from the baseline sample, were analyzed. In the treated Abbreviations: HGBV-C, hepatitis GB virus type C; ALT, alanine aminotransferase; children, serum samples were taken at the end of treatment (range:anti-HBe, antibodies to hepatitis B e antigen; HCV, hepatitis C virus; HBV, hepatitis B 6-9 months) and follow-up period (range: 12-18 months after the virus; IFN, interferon; HBeAg, hepatitis B e antigen; RT-PCR, reverse transcription-nested end of treatment). In the untreated children, two additional serum polymerase chain reaction.samples taken 12 months and 18-30 months after the first sample infection.